KR100904570B1 - 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-피리미딘디아민 - Google Patents
종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-피리미딘디아민 Download PDFInfo
- Publication number
- KR100904570B1 KR100904570B1 KR1020067003056A KR20067003056A KR100904570B1 KR 100904570 B1 KR100904570 B1 KR 100904570B1 KR 1020067003056 A KR1020067003056 A KR 1020067003056A KR 20067003056 A KR20067003056 A KR 20067003056A KR 100904570 B1 KR100904570 B1 KR 100904570B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- alkoxy
- methyl
- Prior art date
Links
- 0 CNS(c1ccccc1Nc(nc(N*)nc1)c1Br)(=O)=O Chemical compound CNS(c1ccccc1Nc(nc(N*)nc1)c1Br)(=O)=O 0.000 description 3
- ANQMORUIOZZXOR-UHFFFAOYSA-N CC(CC=C1CN2C)C(Nc3nc(Nc(c(OC)c4)ccc4N4CCOCC4)ncc3Cl)=C1C2=O Chemical compound CC(CC=C1CN2C)C(Nc3nc(Nc(c(OC)c4)ccc4N4CCOCC4)ncc3Cl)=C1C2=O ANQMORUIOZZXOR-UHFFFAOYSA-N 0.000 description 1
- ZYCXAGUCFFRHHW-UHFFFAOYSA-N CC(N(CC1)CCN1c(cc1)cc([NH+]([O-])[O-])c1OC)=O Chemical compound CC(N(CC1)CCN1c(cc1)cc([NH+]([O-])[O-])c1OC)=O ZYCXAGUCFFRHHW-UHFFFAOYSA-N 0.000 description 1
- XXHKCOWKQMQGET-UHFFFAOYSA-N CCC(C(C)c1cccc(Nc(nc(Nc(ccc(N(CC2)CCC2N2CCCCC2)c2)c2OC)nc2)c2Cl)c1S(=O)=O)N Chemical compound CCC(C(C)c1cccc(Nc(nc(Nc(ccc(N(CC2)CCC2N2CCCCC2)c2)c2OC)nc2)c2Cl)c1S(=O)=O)N XXHKCOWKQMQGET-UHFFFAOYSA-N 0.000 description 1
- GQVZXZORIINEQF-UHFFFAOYSA-N CCC(CC)NS(c(cccc1)c1Nc(nc(Nc(ccc(OC1CN(CC)CC1)c1)c1OCC)nc1)c1Cl)(=O)=O Chemical compound CCC(CC)NS(c(cccc1)c1Nc(nc(Nc(ccc(OC1CN(CC)CC1)c1)c1OCC)nc1)c1Cl)(=O)=O GQVZXZORIINEQF-UHFFFAOYSA-N 0.000 description 1
- UOUMNCDDFNFBNG-HXUWFJFHSA-N CCC(CC)NS(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2O[C@H]2CN(C)CC2)ncc1Cl)(=O)=O Chemical compound CCC(CC)NS(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2O[C@H]2CN(C)CC2)ncc1Cl)(=O)=O UOUMNCDDFNFBNG-HXUWFJFHSA-N 0.000 description 1
- YOYCVJKZYMLVQC-NRFANRHFSA-N CCC(CC)NS(c(cccc1)c1Nc1nc(Nc(c(OCC)c2)ccc2O[C@@H]2CN(C)CC2)ncc1Cl)(=O)=O Chemical compound CCC(CC)NS(c(cccc1)c1Nc1nc(Nc(c(OCC)c2)ccc2O[C@@H]2CN(C)CC2)ncc1Cl)(=O)=O YOYCVJKZYMLVQC-NRFANRHFSA-N 0.000 description 1
- YOYCVJKZYMLVQC-OAQYLSRUSA-N CCC(CC)NS(c(cccc1)c1Nc1nc(Nc(c(OCC)c2)ccc2O[C@H]2CN(C)CC2)ncc1Cl)(=O)=O Chemical compound CCC(CC)NS(c(cccc1)c1Nc1nc(Nc(c(OCC)c2)ccc2O[C@H]2CN(C)CC2)ncc1Cl)(=O)=O YOYCVJKZYMLVQC-OAQYLSRUSA-N 0.000 description 1
- NISHILSJOFWGEW-UHFFFAOYSA-N CCN(CC1)CC1Oc(cc1)cc(OCC)c1Nc(nc1)nc(NC2C=CC=CC2S(CNCC(C)C)(=O)=O)c1Br Chemical compound CCN(CC1)CC1Oc(cc1)cc(OCC)c1Nc(nc1)nc(NC2C=CC=CC2S(CNCC(C)C)(=O)=O)c1Br NISHILSJOFWGEW-UHFFFAOYSA-N 0.000 description 1
- BPUCHTKTPGFFHN-UHFFFAOYSA-N CCN(CC1)CCN1c(cc1OCC)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Br Chemical compound CCN(CC1)CCN1c(cc1OCC)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Br BPUCHTKTPGFFHN-UHFFFAOYSA-N 0.000 description 1
- GVDMSADBJPPLJD-UHFFFAOYSA-N CCN(CC1)CCN1c(cc1OCC)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Cl Chemical compound CCN(CC1)CCN1c(cc1OCC)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Cl GVDMSADBJPPLJD-UHFFFAOYSA-N 0.000 description 1
- JKZAUJMXKHOGGC-UHFFFAOYSA-N CCOc1cc(N2CCN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Br Chemical compound CCOc1cc(N2CCN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Br JKZAUJMXKHOGGC-UHFFFAOYSA-N 0.000 description 1
- VYGDZXFAMXGDBM-UHFFFAOYSA-N CCOc1cc(N2CCN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Cl Chemical compound CCOc1cc(N2CCN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC)(=O)=O)ncc1Cl VYGDZXFAMXGDBM-UHFFFAOYSA-N 0.000 description 1
- XWZDGGDSFVKQGT-IBGZPJMESA-N CCOc1cc(O[C@@H]2CN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC(C)C)(=O)=O)ncc1Cl Chemical compound CCOc1cc(O[C@@H]2CN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC(C)C)(=O)=O)ncc1Cl XWZDGGDSFVKQGT-IBGZPJMESA-N 0.000 description 1
- NLGVFVMNYZVFJK-NRFANRHFSA-N CCOc1cc(O[C@@H]2CN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC2CCCC2)(=O)=O)ncc1Cl Chemical compound CCOc1cc(O[C@@H]2CN(C)CC2)ccc1Nc(nc1Nc(cccc2)c2S(NC2CCCC2)(=O)=O)ncc1Cl NLGVFVMNYZVFJK-NRFANRHFSA-N 0.000 description 1
- HEGUQXXJZHJSGI-HXUWFJFHSA-N CCOc1cc(O[C@H](CC2)CN2I)ccc1Nc(nc1Nc(cccc2)c2S(NC2CCCC2)(=O)=O)ncc1Cl Chemical compound CCOc1cc(O[C@H](CC2)CN2I)ccc1Nc(nc1Nc(cccc2)c2S(NC2CCCC2)(=O)=O)ncc1Cl HEGUQXXJZHJSGI-HXUWFJFHSA-N 0.000 description 1
- YKPATXXNIXWMNF-UHFFFAOYSA-N CN(C)S(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2C(N2CCOCC2)=O)ncc1Cl)(=O)=O Chemical compound CN(C)S(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2C(N2CCOCC2)=O)ncc1Cl)(=O)=O YKPATXXNIXWMNF-UHFFFAOYSA-N 0.000 description 1
- PPBYTGQGFVYLFZ-INIZCTEOSA-N CN(C)S(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2O[C@@H](CC2)CN2I)ncc1Cl)(=O)=O Chemical compound CN(C)S(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2O[C@@H](CC2)CN2I)ncc1Cl)(=O)=O PPBYTGQGFVYLFZ-INIZCTEOSA-N 0.000 description 1
- IQOVKKNJOSUWBS-FQEVSTJZSA-N CN(CC1)C[C@H]1Oc(cc1OC)ccc1Nc(nc1Nc(cccc2)c2S(C2CCCCC2)(=O)=O)ncc1Cl Chemical compound CN(CC1)C[C@H]1Oc(cc1OC)ccc1Nc(nc1Nc(cccc2)c2S(C2CCCCC2)(=O)=O)ncc1Cl IQOVKKNJOSUWBS-FQEVSTJZSA-N 0.000 description 1
- JVXVCEFIYQQHJR-FQEVSTJZSA-N CN(CC1)C[C@H]1Oc(cc1OC)ccc1Nc(nc1Nc(cccc2)c2S(NC2CCCC2)(=O)=O)ncc1Cl Chemical compound CN(CC1)C[C@H]1Oc(cc1OC)ccc1Nc(nc1Nc(cccc2)c2S(NC2CCCC2)(=O)=O)ncc1Cl JVXVCEFIYQQHJR-FQEVSTJZSA-N 0.000 description 1
- MDAHROZOBPNKFR-UHFFFAOYSA-N CNCCc1ccccc1Nc(nc(Nc(ccc(N(CC1)CCC1N1CCCCC1)c1)c1OC)nc1)c1Br Chemical compound CNCCc1ccccc1Nc(nc(Nc(ccc(N(CC1)CCC1N1CCCCC1)c1)c1OC)nc1)c1Br MDAHROZOBPNKFR-UHFFFAOYSA-N 0.000 description 1
- RVNZVWJCTGZHIF-UHFFFAOYSA-N CNS(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2C(N(CC2)CCC2N2CCCCC2)=O)ncc1Br)(=O)=O Chemical compound CNS(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2C(N(CC2)CCC2N2CCCCC2)=O)ncc1Br)(=O)=O RVNZVWJCTGZHIF-UHFFFAOYSA-N 0.000 description 1
- CTPIWWBBOZVNCS-UHFFFAOYSA-N CNS(c(cccc1)c1Nc1nc(Nc(c(OCC2CC2)c2)ccc2N(CC2)CCC2N2CCCCC2)ncc1Cl)(=O)=O Chemical compound CNS(c(cccc1)c1Nc1nc(Nc(c(OCC2CC2)c2)ccc2N(CC2)CCC2N2CCCCC2)ncc1Cl)(=O)=O CTPIWWBBOZVNCS-UHFFFAOYSA-N 0.000 description 1
- DHSXYOWXKKKABN-UHFFFAOYSA-N CNS(c(cccc1)c1Nc1nc(Nc(c(OCC2CC2)c2)ccc2N(CC2)CCC2N2CCOCC2)ncc1Br)(=O)=O Chemical compound CNS(c(cccc1)c1Nc1nc(Nc(c(OCC2CC2)c2)ccc2N(CC2)CCC2N2CCOCC2)ncc1Br)(=O)=O DHSXYOWXKKKABN-UHFFFAOYSA-N 0.000 description 1
- VDOQEOVKPMZKJA-UHFFFAOYSA-N CNS(c1c(CCCc(nc(nc2)Cl)c2[N+](C)([O-])O)cccc1)(=O)=O Chemical compound CNS(c1c(CCCc(nc(nc2)Cl)c2[N+](C)([O-])O)cccc1)(=O)=O VDOQEOVKPMZKJA-UHFFFAOYSA-N 0.000 description 1
- HCPLJTFWHJREKI-UHFFFAOYSA-N CNS(c1ccccc1Nc(nc(nc1)Cl)c1Br)(=O)=O Chemical compound CNS(c1ccccc1Nc(nc(nc1)Cl)c1Br)(=O)=O HCPLJTFWHJREKI-UHFFFAOYSA-N 0.000 description 1
- UAJKCDSLLCLCEO-UHFFFAOYSA-N COc(cc(cc1)N(CC2)CCC2N2CCCCC2)c1Nc(nc1)nc(Nc2c(CCNC3CCCC3)cccc2)c1Cl Chemical compound COc(cc(cc1)N(CC2)CCC2N2CCCCC2)c1Nc(nc1)nc(Nc2c(CCNC3CCCC3)cccc2)c1Cl UAJKCDSLLCLCEO-UHFFFAOYSA-N 0.000 description 1
- PKEYIJHNHAONDX-LJQANCHMSA-N COc1cc(O[C@H](CC2)CN2I)ccc1Nc(nc1Nc(cccc2)c2S(C2CCCCC2)(=O)=O)ncc1Cl Chemical compound COc1cc(O[C@H](CC2)CN2I)ccc1Nc(nc1Nc(cccc2)c2S(C2CCCCC2)(=O)=O)ncc1Cl PKEYIJHNHAONDX-LJQANCHMSA-N 0.000 description 1
- UBTIIZMTNHCGND-UHFFFAOYSA-N Cc(c([N+](O)=O)c1)ccc1-c(cc1)ccc1OC Chemical compound Cc(c([N+](O)=O)c1)ccc1-c(cc1)ccc1OC UBTIIZMTNHCGND-UHFFFAOYSA-N 0.000 description 1
- BAGAORHMZVFECP-UHFFFAOYSA-N Cc1cc(N2CCOCC2)ccc1Nc(nc1NN)ncc1Cl Chemical compound Cc1cc(N2CCOCC2)ccc1Nc(nc1NN)ncc1Cl BAGAORHMZVFECP-UHFFFAOYSA-N 0.000 description 1
- TXJUTRJFNRYTHH-UHFFFAOYSA-N O=C(c(cccc1)c1N1)OC1=O Chemical compound O=C(c(cccc1)c1N1)OC1=O TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Abstract
Description
Claims (25)
- 하나 이상의 제약상 허용되는 담체, 및 활성 성분으로서 역형성 림프종 키나제(ALK) 억제 유효량의 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는, ALK와 관련된 신호 연쇄반응의 기능장애에 의해 유발되는 면역계 장애, 및 고형 종양, 역형성 거대 세포 림프종, 비호지킨 림프종, 염증성 근섬유모세포 종양, 신경모세포종 및 거대 B-세포암으로 이루어진 군에서 선택되는 종양성 질환의 치료 또는 예방용 제약 조성물.<화학식 I>식 중에서,R은 C6-10아릴, C5-10헤테로아릴, C3-12시클로알킬 및 C3-10헤테로시클로알킬로부터 선택되고;R2는 수소, 할로, 시아노 또는 메틸이고;R0 및 R1 은 각각 수소, C1-C8알킬, C2-C8알케닐, C2-C8알키닐, C3-C8시클로알킬, C3-C8시클로알킬C1-C8알킬, C5-C10아릴C1-C8알킬, 히드록시C1-C8알킬, C1-C8알콕시C1-C8알킬, 아미노C1-C8알킬, 할로C1-C8알킬, 비치환 또는 치환된 C5-C10아릴, 비치환 또는 치환된 헤테로시클릴, 히드록시, C1-C8알콕시, 히드록시C1-C8알콕시, C1-C8알콕시C1-C8알콕시, 할로C1-C8알콕시, 비치환 또는 치환된 C5-C10아릴C1-C8알콕시, 비치환 또는 치환된 헤테로시클릴옥시, 또는 비치환 또는 치환된 헤테로시클릴C1-C8알콕시, 비치환 또는 치환된 아미노, C1-C8알킬티오, C1-C8알킬술피닐, C1-C8알킬술포닐, C5-C10아릴술포닐, 할로겐, 카르복시, C1-C8알콕시카르보닐, 비치환 또는 치환된 카르바모일, 비치환 또는 치환된 술파모일, 시아노, 니트로, -S(O)0-2NR12R13, -S(O)0-2R13, -NR12S(O)0-2R13, -C(O)NR12R13, -C(O)R13 및 -C(O)OR13이며; 여기서 R12는 수소 및 C1-6알킬로부터 선택되고; R13은 수소, C1-6알킬 및 C3-12시클로알킬로부터 선택되고;R3은 메틸술포닐, 에틸술포닐, n-프로필술포닐, 이소프로필술포닐, n-부틸술포닐, n-펜틸술포닐, 3-메틸부틸술포닐, 1-에틸프로필술포닐, 이소부틸술포닐, 시클로프로필술포닐, 시클로펜틸술포닐, 시클로헥실술포닐, 벤질술포닐, 페닐술포닐, N-메틸카르바모일, N-에틸카르바모일, N,N-디메틸카르바모일, 이소프로필카르바모일, 피롤리디노카르보닐, 술파모일, N-메틸술파모일, N,N-디메틸술파모일, N-이소프로필술파모일, N-sec-부틸술파모일, N-이소부틸술파모일, N-1-에틸프로필술파모일, N-2,2,2-트리플루오로에틸술파모일, N-시클로프로필술파모일, N-시클로부틸술파모일, N-시클로펜틸술파모일 또는 N-시클로프로필메틸-술파모일이거나;또는 R2와 R3은 함께 1-옥소프로필리덴 또는 2-아자-1-옥소프로필렌 고리를 형성하고;R4는 수소이고;R5는 수소, C1-C8알킬, C1-C8알콕시C1-C8알킬, 할로C1-C8알킬, C1-C8알콕시, 할로겐, 카르복시, C1-C8알콕시카르보닐, 비치환 또는 치환된 카르바모일, 시아노, 또는 니트로이고;R6은 수소이고,R은 비치환되거나 R7, R8, R9, R10 또는 R'10으로 치환되고;R7, R8, R9, R10 및 R'10은 수소, C1-C8알킬, C2-C8알케닐, C2-C8알키닐, C3-C8시클로알킬, C3-C8시클로알킬C1-C8알킬, C5-C10아릴C1-C8알킬, 히드록시C1-C8알킬, C1-C8알콕시C1-C8알킬, 아미노C1-C8알킬, 할로C1-C8알킬, 비치환 또는 치환된 C5-C10아릴, 비치환 또는 치환된 헤테로시클릴, 히드록시, C1-C8알콕시, 히드록시C1-C8알콕시, C1-C8알콕시C1-C8알콕시, 할로C1-C8알콕시, 비치환 또는 치환된 아미노C1-C8알콕시, 비치환 또는 치환된 C5-C10아릴C1-C8알콕시, 비치환 또는 치환된 헤테로시클릴옥시, 또는 비치환 또는 치환된 헤테로시클릴C1-C8알킬, 비치환 또는 치환된 헤테로시클릴C1-C8알콕시, 비치환 또는 치환된 아미노, C1-C8알킬티오, C1-C8알킬술피닐, C1-C8알킬술포닐, C5-C10아릴술포닐, 헤테로시클로술포닐, 할로겐, 카르복시, C1-C8알킬카르보닐, C1-C8알콕시카르보닐, 비치환 또는 치환된 카르바모일, 비치환 또는 치환된 술파모일, 시아노, 니트로, -S(O)0-2NR12R13, -S(O)0-2R12, -C(O)R11, -OXR11, -NR12XR11, -NR12XNR12R13, -OXNR12R13, -OXOR12 및 -XR11로부터 독립적으로 선택된 치환기이거나;R 상의 2개의 인접 치환기는 이들이 부착된 탄소 원자와 함께 비치환 또는 치환된 5 또는 6원 카르보시클릭 고리 또는 N, O 및 S로부터 선택된 0, 1, 2 또는 3개의 헤테로원자를 포함하는 비치환 또는 치환된 5 또는 6원 헤테로시클릭 고리를 형성할 수 있고, 여기서 치환기는 C1-C8알킬, C1-C8알콕시, 할로C1-C8알킬, 히드록시, 아미노, 치환된 아미노, 할로겐, 카르복시, C1-C8알콕시카르보닐, 카르바모일, 시아노 또는 옥소이고;X는 결합 또는 C1-6알킬렌이고;R0 내지 R10, 및 R10'의 정의에서,"헤테로시클릴"은 N, O 및 S로부터 선택된 1, 2 또는 3 개의 헤테로 원자를 포함하는 5 또는 6원 헤테로시클릴이고,용어 "헤티로시클릴옥시"에서 "헤테로시클릴"은 상기 정의한 바와 같고,용어 "헤테로시클로술포닐"에서 "헤테로시클로"는 "헤테로시클릴"과 동일한 의미를 갖고,"치환된 C5-C10 아릴" 및 "치환된 C5-C10아릴C1-C8알콕시"는 C1-C8-알킬, C1-C8-알콕시C1-C8-알킬, 할로-C1-C8-알킬, 히드록시, C1-C8-알콕시, 메틸렌디옥시, 아미노, 메틸아미노, 디메틸아미노, 프로필아미노, 벤질아미노, 히드록시에탤-메틸아미노, 디(히드록시에틸)아미노, 디메틸아미노에틸아미노, 아세틸아미노, 아세틸-메틸-아미노, 벤조일아미노, 메틸술포닐아미노, 페닐술포닐아미노, 할로겐, 카르복시, C1-C8-알콕시카르보닐, 카르바모일, 술파모일, 시아노 및 니트로에서 선택된 치환기에 의해 치환되고,"치환된 헤테로시클릴", "치환된 헤테로시클릴옥시" 및 "치환된 헤테로시클릴 C1-C8 알콕시"는 C1-C8-알킬, 히드록시-C1-C8-알킬, C1-C8-알콕시C1-C8-알킬, C1-C8-알콕시-C1-C8-알콕시, 할로-C1-C8-알킬, 히드록실, C1-C8-알콕시, 메틸렌디옥시, 아미노, 메틸아미노, 디메틸아미노, 프로필아미노, 벤질아미노, 히드록시에탤-메틸아미노, 디(히드록시에틸)아미노, 디메틸아미노에틸아미노, 아세틸아미노, 아세틸-메틸-아미노, 벤조일아미노, 메틸술포닐아미노, 페닐술포닐아미노, 할로겐, 카르복시, C1-C8-알킬카르보닐, C1-C8-알콕시카르보닐, 카르바모일, C1-C8-알킬카르바모일, 시아노, 옥소, 인돌릴, 피롤리디닐, 피롤리도닐, 이미다졸릴, N-메틸이미다졸릴, 벤즈이미다졸릴, S,S-디옥소이소티아졸리디닐, 피페리딜, 4-아세틸아미노피페리딜, 4-메틸아미노카르바모일피페리딜, 4-피페리디노피페리딜, 4-시아노피페리딜, 피페라지닐, N-메틸피페라지닐, N-(2-히드록시에틸)피페라지닐, 모르폴리닐, 1-아자-2,2-디옥소-2-티아시클로헥실 또는 술포라닐에서 선택된 치환기에 의해 치환되고,"치환된 카르바모일"은 C1-C8-알킬, C2-C8-알케닐, C2-C8-알키닐, C3-C8-시클로알킬, C3-C8-시클로알킬C1-C8-알킬, C6-C10아릴-C1-C8알킬, 히드록시C1-C8알킬, C1-C8알콕시C1-C8알킬, 할로-C1-C8-알킬, 비치환 또는 상기 정의된 바와 같은 치환된 C5-C10아릴, 및 아미노C1-C8-알킬에서 선택된 치환기에 의해 치환된 카르바모일이거나, 카르바모일기의 치환기 및 질소 원자가 O, N 및 S에서 선택된 0, 1 또는 2 개의 헤테로 원자를 추가로 포함하는 5- 또는 6-원 헤테로시클릴을 나타내는 카르바모일이고,"치환된 술파모일"은 C1-C8-알킬, C2-C8-알케닐, C2-C8-알키닐, C3-C8-시클로알킬, C3-C8-시클로알킬C1-C8-알킬, C6-C10아릴-C1-C8알킬, 히드록시C1-C8알킬, C1-C8알콕시C1-C8알킬, 할로-C1-C8-알킬, 비치환 또는 상기 정의된 바와 같은 치환된 C5-C10아릴, 및 아미노C1-C8-알킬에서 선택된 치환기에 의해 치환된 술파모일이거나, 술파모일기의 치환기 및 질소 원자가 O, N 및 S에서 선택된 0, 1 또는 2 개의 헤테로 원자를 추가로 포함하는 5- 또는 6-원 헤테로시클릴을 나타내고,R, R0 내지 R10, 및 R10'의 정의에서, "치환된 아미노"는 메틸, 디메틸, 프로필, 벤질, 히드록시에틸-메틸, 디(히드록시에틸), 디메틸아미노에틸, 아세틸, 아세틸-메틸, 벤조일, 메틸술포닐 또는 페닐술포닐에서 선택된 치환기에 의해 치환되고,R11은 C6-10아릴, C5-10헤테로아릴, C3-12시클로알킬 및 C3-10헤테로시클로알킬로부터 독립적으로 선택되고;R11의 아릴, 헤테로아릴, 시클로알킬 또는 헤테로시클로알킬은 C1-6알킬, C1-6알킬로 치환될 수 있는 C3-10헤테로시클로알킬-C0-4알킬, -C(O)R12, -C(O)NR12R13, -XNR12R13, -NR12XNR12R13 및 -NR12C(O)R13으로부터 독립적으로 선택된 1 내지 3개의 라디칼로 치환될 수 있으며, 여기서 X는 결합 또는 C1-6알킬렌이고; R12 및 R13은 수소 및 C1-6알킬로부터 독립적으로 선택된다.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 역형성 림프종 키나제(ALK)와 관련된 신호 연쇄반응의 기능장애에 의해 유발되는 질환이 역형성 거대 세포 림프종, 비호지킨 림프종, 염증성 근섬유모세포 종양, 신경모세포종 또는 거대 B-세포 림프종인 제약 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제12항에 있어서, 역형성 림프종 키나제(ALK)와 관련된 신호 연쇄반응의 기능장애에 의해 유발되는 질환이 뉴클레오포스민(NPM)과 ALK의 유전자 융합에 기초한 것인 제약 조성물.
- 제12항에 있어서, 역형성 림프종 키나제(ALK)와 관련된 신호 연쇄반응의 기능장애에 의해 유발되는 질환이 비근육 트로포미오신(TPM3)과 ALK의 유전자 융합에 기초한 것인 제약 조성물.
- 제12항에 있어서, 역형성 림프종 키나제(ALK)와 관련된 신호 연쇄반응의 기능장애에 의해 유발되는 질환이 ALK 융합 단백질 CLTC-ALK에 기초한 것인 제약 조성물.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0319227A GB0319227D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
GB0319227.5 | 2003-08-15 | ||
GB0322370A GB0322370D0 (en) | 2003-09-24 | 2003-09-24 | Organic compounds |
GB0322370.8 | 2003-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060039938A KR20060039938A (ko) | 2006-05-09 |
KR100904570B1 true KR100904570B1 (ko) | 2009-06-25 |
Family
ID=34196260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067003056A KR100904570B1 (ko) | 2003-08-15 | 2004-08-13 | 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-피리미딘디아민 |
Country Status (32)
Country | Link |
---|---|
US (2) | US7893074B2 (ko) |
EP (2) | EP1660458B1 (ko) |
JP (2) | JP4607879B2 (ko) |
KR (1) | KR100904570B1 (ko) |
AR (1) | AR045458A1 (ko) |
AT (1) | ATE542801T1 (ko) |
AU (2) | AU2004264382A1 (ko) |
BR (2) | BR122019017579B8 (ko) |
CA (1) | CA2533320A1 (ko) |
CO (1) | CO5680434A2 (ko) |
CY (2) | CY1112571T1 (ko) |
DK (2) | DK2287156T3 (ko) |
EC (1) | ECSP066371A (ko) |
ES (2) | ES2424881T3 (ko) |
HK (1) | HK1091813A1 (ko) |
HR (2) | HRP20120335T1 (ko) |
IL (1) | IL173129A0 (ko) |
IS (1) | IS2873B (ko) |
MA (1) | MA27994A1 (ko) |
MX (1) | MXPA06001759A (ko) |
MY (1) | MY147449A (ko) |
NO (1) | NO333306B1 (ko) |
NZ (1) | NZ585188A (ko) |
PL (2) | PL1660458T3 (ko) |
PT (2) | PT2287156E (ko) |
RU (1) | RU2395500C2 (ko) |
SG (1) | SG145749A1 (ko) |
SI (2) | SI1660458T1 (ko) |
TN (1) | TNSN06052A1 (ko) |
TW (1) | TWI378923B (ko) |
WO (1) | WO2005016894A1 (ko) |
ZA (1) | ZA200600464B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013176503A1 (ko) | 2012-05-24 | 2013-11-28 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
WO2014025128A1 (ko) * | 2012-08-10 | 2014-02-13 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
KR20110010824A (ko) | 2003-01-14 | 2011-02-07 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료 |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2004313181A (ja) * | 2003-04-02 | 2004-11-11 | Canon Inc | 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法 |
KR20120062863A (ko) | 2003-07-30 | 2012-06-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물 |
CA2533320A1 (en) * | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2007028445A1 (en) * | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
TW200740805A (en) * | 2005-07-15 | 2007-11-01 | Glaxo Group Ltd | Novel compounds |
GB0517329D0 (en) * | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007085540A1 (en) * | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
DK1984357T3 (da) | 2006-02-17 | 2014-01-13 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP2450437B1 (en) | 2006-04-14 | 2017-05-17 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
EP2537830A1 (en) * | 2006-12-08 | 2012-12-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
CN101563327A (zh) * | 2006-12-19 | 2009-10-21 | 健泰科生物技术公司 | 嘧啶类激酶抑制剂 |
TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
ES2593486T3 (es) | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
BRPI0814821A2 (pt) | 2007-07-16 | 2015-02-03 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para preparar um composto |
US7981903B2 (en) | 2007-08-08 | 2011-07-19 | Glaxosmithkline Llc | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer |
WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
BRPI0815979A2 (pt) * | 2007-08-28 | 2017-06-13 | Irm Llc | compostos e composições com inibidores de quinase, bem como uso dos mesmos |
EP2234986A2 (en) | 2007-12-20 | 2010-10-06 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
WO2009126515A1 (en) * | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
CN103224497A (zh) | 2008-04-22 | 2013-07-31 | 波托拉医药品公司 | 蛋白激酶抑制剂 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
ES2472323T3 (es) * | 2008-06-17 | 2014-06-30 | Astrazeneca Ab | Compuestos de piridina |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
EP3549934A1 (en) * | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
JO3067B1 (ar) * | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
TWI491605B (zh) | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | 新穎化合物 |
EP2376491B1 (en) | 2008-12-19 | 2015-03-04 | Cephalon, Inc. | Pyrrolotriazines as alk and jak2 inhibitors |
US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
ES2423804T3 (es) | 2009-04-03 | 2013-09-24 | Cellzome Gmbh | Métodos para la identificación de moléculas que interaccionan con cinasas y para la purificación de proteínas de cinasa |
US20120040955A1 (en) | 2009-04-14 | 2012-02-16 | Richard John Harrison | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
MX2011013325A (es) * | 2009-06-10 | 2012-04-30 | Abbott Lab | 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa. |
US20120142667A1 (en) * | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
EP2443095A1 (en) * | 2009-06-18 | 2012-04-25 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
EP2443106A1 (en) * | 2009-06-18 | 2012-04-25 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
EP2475648A1 (en) * | 2009-09-11 | 2012-07-18 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
US20130137709A1 (en) * | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
JP5957460B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | 複素環式化合物またはその使用 |
WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
US8846928B2 (en) | 2010-11-01 | 2014-09-30 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
US20130317029A1 (en) | 2010-11-01 | 2013-11-28 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
US9133224B2 (en) | 2010-11-29 | 2015-09-15 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
JP5916752B2 (ja) * | 2010-12-17 | 2016-05-11 | ノバルティス アーゲー | 5−クロロ−n2−(2−イソプロポキシ−5−メチル−4−ピペリジン−4−イル−フェニル)−n4[2−(プロパン−2−スルホニル)−フェニル]−ピリミジン−2,4−ジアミンの結晶形 |
UY33817A (es) | 2010-12-21 | 2012-07-31 | Boehringer Ingelheim Int | ?nuevas oxindolpirimidinas bencílicas?. |
JP2012153674A (ja) | 2011-01-28 | 2012-08-16 | Astellas Pharma Inc | ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体 |
ES2543567T3 (es) * | 2011-02-02 | 2015-08-20 | Novartis Ag | Métodos de utilización de inhibidores de ALK |
ES2691673T3 (es) | 2011-02-17 | 2018-11-28 | Cancer Therapeutics Crc Pty Limited | Inhibidores de Fak |
DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
WO2012127032A1 (en) | 2011-03-24 | 2012-09-27 | Chemilia Ab | Novel pyrimidine derivatives |
US9249124B2 (en) | 2011-03-30 | 2016-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase inhibitors and methods of making and using thereof |
MX351754B (es) | 2011-04-22 | 2017-10-27 | Signal Pharm Llc | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas. |
EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
AU2012340555B2 (en) | 2011-11-23 | 2016-10-20 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
NZ630251A (en) | 2012-03-06 | 2016-02-26 | Cephalon Inc | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
WO2013138495A1 (en) | 2012-03-15 | 2013-09-19 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
CN104284584B (zh) | 2012-03-15 | 2019-06-04 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的盐 |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
KR102156398B1 (ko) * | 2012-11-06 | 2020-09-15 | 상하이 포천 파마슈티컬 씨오 엘티디 | Alk 키나아제 억제제 |
CN103804299A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2014193932A1 (en) | 2013-05-29 | 2014-12-04 | Cephalon, Inc. | Pyrrolotriazines as alk inhibitors |
WO2014203152A1 (en) | 2013-06-18 | 2014-12-24 | Novartis Ag | Pharmaceutical combinations |
JP6510510B2 (ja) * | 2013-07-11 | 2019-05-08 | ベータ ファーマシューティカルズ カンパニー リミテッド | プロテインチロシンキナーゼモジュレーター及び使用方法 |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
WO2015038868A1 (en) * | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
EP3066215B1 (en) | 2013-11-06 | 2019-04-24 | The United States of America, represented by the Secretary, Department of Health and Human Services | Method for subtyping lymphoma types by means of expression profiling |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
WO2015164604A1 (en) * | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) * | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
HUE051693T2 (hu) | 2014-10-21 | 2021-03-29 | Ariad Pharma Inc | 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
AU2016297784B2 (en) | 2015-07-24 | 2020-12-24 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CN106699743B (zh) * | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
CN106883213B (zh) * | 2015-12-15 | 2021-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 一种egfr和alk激酶的双重抑制剂 |
US10710993B2 (en) * | 2016-06-27 | 2020-07-14 | Hangzhou REX Pharmaceutical Co., LTD. | Benzofuran pyrazole amine kinase inhibitor |
EP4001273A3 (en) | 2016-08-29 | 2022-08-24 | The Regents Of The University Of Michigan | Aminopyrimidines as alk inhibitors |
KR101876514B1 (ko) | 2016-11-08 | 2018-07-10 | 한국화학연구원 | 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물 |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
EP3586848B1 (en) | 2017-02-24 | 2021-09-01 | Daegu-Gyeongbuk Medical Innovation Foundation | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer |
JOP20190281A1 (ar) * | 2017-06-13 | 2019-12-02 | Korea Res Inst Chemical Tech | مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه |
SG11202001282UA (en) | 2017-09-07 | 2020-03-30 | Revolution Medicines Inc | Shp2 inhibitor compositions and methods for treating cancer |
KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
CN109369721B (zh) * | 2017-12-21 | 2024-05-14 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的芳基磷氧化物 |
AU2019247498A1 (en) | 2018-04-05 | 2020-11-26 | Sumitomo Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
CN113473990A (zh) | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
WO2020088390A1 (zh) * | 2018-10-29 | 2020-05-07 | 江苏先声药业有限公司 | 作为第四代egfr抑制剂的嘧啶吡唑类化合物 |
WO2020147702A1 (en) * | 2019-01-17 | 2020-07-23 | Betta Pharmaceuticals Co., Ltd | Egfr inhibitors, compositions and methods thereof |
CA3130083A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
KR20220028075A (ko) | 2019-07-03 | 2022-03-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 |
AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
EP4055028A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
JP7390487B2 (ja) | 2019-12-03 | 2023-12-01 | サムジン ファーマシューティカル カンパニー,リミテッド | 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体 |
JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ,インコーポレイテッド | Shp2阻害剤投薬およびがんを処置する方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4110340A1 (en) * | 2020-02-25 | 2023-01-04 | Dana-Farber Cancer Institute, Inc. | Potent and selective degraders of alk |
AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
JP2024501280A (ja) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | Sos1阻害剤およびその使用 |
WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105400A1 (en) * | 1982-09-30 | 1984-04-18 | Mitsubishi Denki Kabushiki Kaisha | Process for preparing a heat resistant soft composite |
WO2003018021A1 (en) * | 2001-08-22 | 2003-03-06 | Amgen Inc. | 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003063794A2 (en) * | 2002-02-01 | 2003-08-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL129020C (ko) | 1964-12-15 | |||
US3432493A (en) * | 1966-06-27 | 1969-03-11 | Abbott Lab | Substituted sulfanilamides |
US3367149A (en) * | 1966-12-15 | 1968-02-06 | Minnesota Mining & Mfg | Radiant white light source |
JPS5490121A (en) * | 1977-11-28 | 1979-07-17 | Boettcher Barry | Neutral copper bonded body and antiinflaming agent |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE69839735D1 (de) * | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
ID26291A (id) | 1998-03-27 | 2000-12-14 | Janssen Pharmaceutica Nv | Turunan-turunan pirimidina penghambat hiv |
ES2274634T3 (es) * | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
EP1184376B1 (en) | 1999-06-09 | 2005-02-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
CN1429222A (zh) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
US6376770B1 (en) * | 2000-02-28 | 2002-04-23 | Douglas Hyde | Quick connecting universal electrical box and wiring system |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US20020132823A1 (en) | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
US20030139435A1 (en) * | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
ES2303565T3 (es) * | 2001-11-01 | 2008-08-16 | Janssen Pharmaceutica Nv | Derivados de aminobenzamida como inhibidores de la glucogeno sintasa cinasa 3beta. |
MXPA04007637A (es) * | 2002-02-08 | 2004-11-10 | Smithkline Beecham Corp | Compuestos de pirimidina. |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003231231A1 (en) * | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
MXPA05001096A (es) * | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
ES2598404T3 (es) * | 2003-02-07 | 2017-01-27 | Janssen Pharmaceutica Nv | Derivados de pirimidina para la prevención de infección por el VIH |
ES2325440T3 (es) * | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP1781659B1 (en) * | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
CN100404536C (zh) * | 2003-07-16 | 2008-07-23 | 詹森药业有限公司 | 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物 |
DE602004032446D1 (de) * | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
CA2533320A1 (en) * | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
EP1663992A1 (en) * | 2003-09-18 | 2006-06-07 | Novartis AG | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
-
2004
- 2004-08-13 CA CA002533320A patent/CA2533320A1/en not_active Abandoned
- 2004-08-13 SG SG200806063-4A patent/SG145749A1/en unknown
- 2004-08-13 BR BR122019017579A patent/BR122019017579B8/pt active IP Right Grant
- 2004-08-13 RU RU2006107785/04A patent/RU2395500C2/ru active
- 2004-08-13 EP EP04764093A patent/EP1660458B1/en active Active
- 2004-08-13 ES ES10010291T patent/ES2424881T3/es active Active
- 2004-08-13 AU AU2004264382A patent/AU2004264382A1/en not_active Abandoned
- 2004-08-13 TW TW093124290A patent/TWI378923B/zh active
- 2004-08-13 WO PCT/EP2004/009099 patent/WO2005016894A1/en active Application Filing
- 2004-08-13 PL PL04764093T patent/PL1660458T3/pl unknown
- 2004-08-13 US US10/568,367 patent/US7893074B2/en active Active
- 2004-08-13 KR KR1020067003056A patent/KR100904570B1/ko active Protection Beyond IP Right Term
- 2004-08-13 DK DK10010291.2T patent/DK2287156T3/da active
- 2004-08-13 MY MYPI20043301A patent/MY147449A/en unknown
- 2004-08-13 EP EP10010291.2A patent/EP2287156B1/en active Active
- 2004-08-13 NZ NZ585188A patent/NZ585188A/en not_active IP Right Cessation
- 2004-08-13 MX MXPA06001759A patent/MXPA06001759A/es active IP Right Grant
- 2004-08-13 JP JP2006522998A patent/JP4607879B2/ja active Active
- 2004-08-13 PT PT100102912T patent/PT2287156E/pt unknown
- 2004-08-13 BR BRPI0413616A patent/BRPI0413616B8/pt active IP Right Grant
- 2004-08-13 PL PL10010291T patent/PL2287156T3/pl unknown
- 2004-08-13 AT AT04764093T patent/ATE542801T1/de active
- 2004-08-13 SI SI200431849T patent/SI1660458T1/sl unknown
- 2004-08-13 PT PT04764093T patent/PT1660458E/pt unknown
- 2004-08-13 DK DK04764093.3T patent/DK1660458T3/da active
- 2004-08-13 ES ES04764093T patent/ES2380206T3/es active Active
- 2004-08-13 SI SI200432067T patent/SI2287156T1/sl unknown
- 2004-08-17 AR ARP040102945A patent/AR045458A1/es active IP Right Grant
-
2006
- 2006-01-12 IL IL173129A patent/IL173129A0/en unknown
- 2006-01-17 ZA ZA2006/00464A patent/ZA200600464B/en unknown
- 2006-02-14 TN TNP2006000052A patent/TNSN06052A1/en unknown
- 2006-02-15 EC EC2006006371A patent/ECSP066371A/es unknown
- 2006-02-17 MA MA28815A patent/MA27994A1/fr unknown
- 2006-02-20 CO CO06016492A patent/CO5680434A2/es active IP Right Grant
- 2006-03-13 IS IS8349A patent/IS2873B/is unknown
- 2006-03-15 NO NO20061214A patent/NO333306B1/no unknown
- 2006-11-07 HK HK06112236.3A patent/HK1091813A1/xx unknown
-
2008
- 2008-09-29 AU AU2008229685A patent/AU2008229685B2/en active Active
-
2010
- 2010-07-16 JP JP2010162177A patent/JP2010241830A/ja active Pending
-
2011
- 2011-01-04 US US12/984,519 patent/US20110098280A1/en not_active Abandoned
-
2012
- 2012-03-22 CY CY20121100300T patent/CY1112571T1/el unknown
- 2012-04-16 HR HRP20120335TT patent/HRP20120335T1/hr unknown
-
2013
- 2013-08-01 HR HRP20130724TT patent/HRP20130724T1/hr unknown
- 2013-08-13 CY CY20131100696T patent/CY1117015T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105400A1 (en) * | 1982-09-30 | 1984-04-18 | Mitsubishi Denki Kabushiki Kaisha | Process for preparing a heat resistant soft composite |
WO2003018021A1 (en) * | 2001-08-22 | 2003-03-06 | Amgen Inc. | 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003063794A2 (en) * | 2002-02-01 | 2003-08-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013176503A1 (ko) | 2012-05-24 | 2013-11-28 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
WO2014025128A1 (ko) * | 2012-08-10 | 2014-02-13 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
US9199944B2 (en) | 2012-08-10 | 2015-12-01 | Korea Research Institute Of Chemical Technology | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100904570B1 (ko) | 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-피리미딘디아민 | |
KR101148261B1 (ko) | 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-디(페닐아미노)피리미딘 | |
KR100894349B1 (ko) | 피리미딘 유도체 | |
KR20070054223A (ko) | 피리미딘 유도체 | |
DK2091918T3 (en) | Compounds and Compositions as Protein Kinase Inhibitors | |
EP2311807B1 (en) | Compounds and composition as protein kinase inhibitors | |
AU2009213036B2 (en) | Pyrimidine urea derivatives as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130522 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140521 Year of fee payment: 6 |
|
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20150519 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160517 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170601 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190530 Year of fee payment: 11 |